High prevalence of sacroiliac bone marrow edema on MRI in postpartum women : a temporary phenomenon by Renson, Thomas et al.
OP0038 HIGH PREVALENCE OF SACROILIAC BONE MARROW
EDEMA ON MRI IN POSTPARTUM WOMEN: A
TEMPORARY PHENOMENON
Thomas Renson1,2, Ann-Sophie De Craemer1,2, Anaïs Depicker1,
Liselotte Deroo1,2, Manouk de Hooge1,2, Nele Herregods3, Lennart Jans3,
Gaëlle Varkas1,2, Kristien Roelens4, Isabelle Dehaene4, Philippe Carron1,2, Filip
van den Bosch1,2, Dirk Elewaut1,2. 1Ghent University Hospital, Rheumatology,
Ghent, Belgium; 2VIB Inflammation Research Center, Ghent University, Ghent,
Belgium; 3Ghent University Hospital, Radiology, Ghent, Belgium; 4Ghent University
Hospital, Obstetrics, Ghent, Belgium
Background: Magnetic Resonance Imaging (MRI) is a sensitive method for
detection of sacroiliitis. However, recently, concerns have been raised about its
specificity. In contrast to radiographic spondyloarthritis (SpA), non-radiographic
SpA has a more equal sex distribution. Hence, in young women with back pain a
broad differential diagnosis has to be considered. In clinical practice, women
occasionally present with inflammatory(-like) low back pain, following pregnancy
and childbirth. Up until now, little is known regarding the presence of SpA-like MRI
lesions in postpartum women. We hypothesized that physical stress on the pelvis
during pregnancy may lead to signs of bone marrow edema on MRI.
Objectives: To explore (A) the association between pregnancy and giving birth
on the one hand, and the occurrence of MRI lesions compatible with SpA on the
other hand; and (B) if these lesions are transient.
Methods: Twenty-five women underwent an MRI of the sacroiliac joints (SIJ) in
the first 10 days after vaginal delivery. The scan was repeated after 6 months.
Both time points were scored in pairs by 3 trained readers, blinded for time
sequence and subject characteristics. MRI assessment was done on 6 consecu-
tive slices for inflammatory and structural SpA-like lesions; bone marrow edema
(BME), capsulitis, enthesitis, high signal intensity in joint space, erosions, fatty
lesions, sclerosis and (partial) ankylosis. In addition, the Assessment of Spondy-
loArthritis international Society (ASAS) definition of a positive MRI-SIJ was
applied. MRI reader scores were reported as 2 out of 3 (median) scores.
Results: Twenty out of 25 (80.0%) subjects displayed BME; the median SPARCC
score was 5 (IQR 1-11) (see table). One subject was lost to follow-up. After 6
months, 11 out of 24 (45.8%) subjects still showed BME; however, median
SPARCC score dropped to 0 (IQR 0-1) (p = 0.002). At baseline, 16 out of 25
(64.0%) participants had a positive MRI-SIJ according to the ASAS definition,
reducing to 4 out of 24 (16.7%) after 6 months (p = 0.002). 75.5% of the baseline
lesions were located in the anterior part of the SIJ; 57.3% situated on the iliac
side. Structural lesions were rarely detected in this study population (see table).
Table: Number of MRI-SIJ lesions in 25 postpartum women.
Baseline 6 months




SPARCC (/72) 5 1 – 11 1 – 8 0 0 – 1 0 – 1
Capsulitis (/12) 0 0 – 0 0 – 0 0 0 – 0 0 – 0
Enthesitis (/12) 0 0 – 0 0 – 0 0 0 – 0 0 – 0
High signal intensity (/12) 0 0 – 4 0 – 3 0 0 – 0 0 – 0




Erosions (/48) 0 0 – 0 0 – 0 0 0 – 0 0 – 0
Fatty lesions (/48) 0 0 – 1 0 – 0 0 0 – 0 0 – 0
Sclerosis (/48) 0 0 – 0 0 – 0 0 0 – 0 0 – 0
Partial ankylosis (/48) 0 0 – 0 0 – 0 0 0 – 0 0 – 0
Ankylosis (/48) 0 0 – 0 0 – 0 0 0 – 0 0 – 0
Figure: Baseline MRI T2 short tau inversion recovery (STIR) images of sacroiliac bone
marrow edema in a 33-year old postpartum woman.
Conclusion: A very high prevalence of sacroiliac BME on MRI was seen in
women immediately postpartum with 64.0% even having a positive MRI for sacroi-
liitis according to the ASAS definition. A significant decrease in BME was seen
over 6 months time, yet a substantial fraction continued to display BME after follow
up. History of a recent pregnancy is crucial to take into account when interpreting
an MRI-SIJ. In case of a recent pregnancy and clinical suspicion of SpA, it may be
wise to postpone MRI-SIJ imaging until at least 6 months after the delivery.
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Background: Traditional DMARDs have limited efficacy in primary Sjögren’s
syndrome (pSS) and, so far, no biologic DMARDs are approved for its systemic
treatment. Two open-label studies suggested abatacept (ABA) may have a bene-
ficial effect on disease activity and had an acceptable safety profile in pSS.1,2
Objectives: To examine the efficacy and safety of ABA vs placebo (PBO) in
patients (pts) with moderate-to-severe pSS.
Methods: In this Phase III, double-blind, PBO-controlled study (NCT02915159),
adult pts meeting the 2016 ACR-EULAR criteria for pSS with EULAR Sjögren’s
Syndrome Disease Activity Index (ESSDAI) 5 were randomised to receive ABA
125 mg SC weekly or PBO for 168 days (24 weeks), followed by a 197-day (365-
day in Japan) open-label period of ABA treatment. All pts had a 168-day post-
treatment follow-up period. Randomisation was stratified by corticosteroid (CS)
and hydroxychloroquine (HCQ) use, enrolment in Japan (yes/no) and stimulated
whole salivary flow (SWSF; < or 0.1 mL/min). The primary endpoint was mean
change in ESSDAI at Day 169. Key secondary endpoints included mean changes
in EULAR Sjögren’s Syndrome Patient Reported Index and SWSF at Day 169.
Other secondary endpoints included objective measures of eye and mouth dry-
ness, DAS28 (CRP), patient-reported outcomes and biomarkers. Hierarchical
testing for the primary and two key secondary endpoints was done to preserve
overall type I error of 5%.
Results: A total of 187 (ABA, 92; PBO, 95) pts were randomised and received1
dose of study drug. Baseline characteristics were comparable between treatment
groups: mean (SD) age was 52 (12.9) years, 95% of pts were female, 64% were
white, 40% were receiving concomitant stable-dose HCQ and 25% oral CS (£10
mg/day prednisone equivalent). Mean (SD) baseline ESSDAI score was 9.4 (4.3)
(ABA, 8.7 [3.4] vs PBO, 10.1 [5.0]). At Day 169, no significant differences were
seen between ABA- and PBO-treated pts for the primary or key secondary effi-
cacy outcomes (Table 1). Applying the Benjamini–Hochberg method (with a false
discovery rate of 5%) at Day 169, significant treatment differences were observed
for 5/12 biomarkers (post hoc analysis) (Table 1). Serious AEs related to the study
drug occurred in 3% of ABA- and 1% of PBO-treated pts. Related AEs occurred in
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